PHASE II STUDY OF SHORTENED-DURATION IMMUNOSUPPRESSION FOLLOWING NONMYELOABLATIVE PERIPHERAL BLOOD STEM CELL TRANSPLANT WITH HIGH-DOSE POSTTRANSPLANTATION CYCLOPHOSPHAMIDE IN MALIGNANCIES THAT ARE CHALLENGING TO ENGRAFT
Brief description of study
This is an open label phase II single arm study of peripheral blood stem cell transplantation and posttransplantation cyclophosphamide, using HLA full match or haploidentical related donors, in hematological malignancies including those difficult to engraft. this trial is a modification of protocols successfully done at several other centers, in which stem cell donors may include siblings that were otherwise rejected for not being a "perfect match," as well as children, parents of the recipient. A novel form of immune suppression is used to prevent "graft vs. host disease" and improve the "take" of the donor stem cells.
Clinical Study Identifier: s17-00042
ClinicalTrials.gov Identifier: NCTs17-00042
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
